Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study.
Liv S ThieleKazi Ishtiak-AhmedJanne P ThirstrupEsben AgerboCarin A T C LunenburgDaniel J MüllerChristiane GassePublished in: Pharmaceuticals (Basel, Switzerland) (2022)
The CYP2C19 and CYP2D6 PM phenotype statuses were associated with outcomes in children, adolescents, and young adults with depression with incident new-use of (es)citalopram, sertraline, or fluoxetine, therefore indicating the utility of PGx testing, particularly in younger people, for PGx-guided antidepressant treatment.